<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570943</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2020-04 GAB</org_study_id>
    <nct_id>NCT04570943</nct_id>
  </id_info>
  <brief_title>Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer</brief_title>
  <acronym>GABRINOX-ART</acronym>
  <official_title>Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine/Nab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate the efficacy of intensified and sequential&#xD;
      chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the&#xD;
      Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced&#xD;
      pancreatic adenocarcinoma.&#xD;
&#xD;
      The study will also demonstrate the feasibility of combining this intensified chemotherapy&#xD;
      with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy&#xD;
      by Gabrinox regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer was the third cause of death by cancer worldwide in 2016, surpassing breast&#xD;
      cancer. It is estimated that in 2030, pancreatic cancer will become the second cause of death&#xD;
      by cancer after lung cancer.&#xD;
&#xD;
      Its prognosis is very poor, with an overall survival (OS) at 5 years, all stages included, of&#xD;
      5.5%. According to the French cancer registry network (FRANCIM), its incidence has more than&#xD;
      doubled in men and women between 1990 and 2018. The world standardized incidence rates for&#xD;
      men and women were 5.2% and 2.7% in 1990 and 11% and 7% in 2018, respectively. This means a&#xD;
      yearly annual increase of 2.7 for men and of 3.8 for women. The often late diagnosis, in 50%&#xD;
      of cases at stage 4, and the limited treatment options explain the very low survival rate at&#xD;
      5 years.&#xD;
&#xD;
      Currently, only surgery associated with adjuvant chemotherapy for 6 months allows doubling&#xD;
      this survival rate. However, this situation concerns only 20% of cases. Indeed, 50% of&#xD;
      pancreatic cancers are discovered at stage 4, and in 30% of patients cancer is detected when&#xD;
      not resectable and non-metastatic (i.e. borderline resectable or locally advanced). To make&#xD;
      an unresectable cancer resectable is one of the therapeutic strategies under development.&#xD;
      However, treatment of locally advanced pancreatic cancer (LAPC) is not standardized.&#xD;
      Chemotherapy is a used strategy, but 30% of cases will progress to metastatic disease.&#xD;
      Therefore, the need in LAPC to control not only the local disease but also micro-metastases&#xD;
      has led to the development of combined strategies with chemotherapy and optimal radiotherapy.&#xD;
&#xD;
      For LAPC, chemotherapy is based on two drug combinations that are classically used for the&#xD;
      first-line treatment of metastatic disease: FOLFIRINOX (FFX) (association of 5FU, Oxaliplatin&#xD;
      and Irinotecan) and GEMBRAX (GA) (association of gemcitabine and nab-paclitaxel). Their&#xD;
      association has been validated by phase 3 studies showing that compared with gemcitabine&#xD;
      alone, they allow increasing the response rate by three times (30%), and almost doubling the&#xD;
      median survival and progression-free survival, but with higher grade 3 hematologic and&#xD;
      neurological toxicities.&#xD;
&#xD;
      FFX and GA have been assessed also in LAPC. Retrospective studies confirmed the high response&#xD;
      rate, 30 to 80% according to the study, and a median survival of 9 to 30 months. Recently,&#xD;
      two phase 2 studies, evaluated GA alone and GA followed by FFX, respectively, for LAPC, and&#xD;
      confirmed the efficacy, with a response rate of 30% and a secondary resection rate of 15% and&#xD;
      30.6%, respectively. Moreover, in patients who underwent tumour resection after treatment,&#xD;
      survival was longer than in those not operated (27.4 vs 14.2 months; Hazard Ratio (HZ) =&#xD;
      0.45; p = 0.0035). Overall Survival (OS) (n= 165 patients) was 17.2 months.&#xD;
&#xD;
      GABRINOX is a sequential treatment with GA and then FFX with the aim of limiting&#xD;
      chemoresistance, decreasing toxicities and improving dose intensity.&#xD;
&#xD;
      The feasibility and tolerance of this approach as first-line treatment of metastatic disease&#xD;
      were validated in a phase 1 study, and its efficacy in a phase 2 study in which the primary&#xD;
      objective was reached: objective response rate of 64.9%, disease control rate of 84.2%,&#xD;
      progression-free survival (PFS) of 10.5 months, and Overall Survival (OS) of 15.1 months. Its&#xD;
      tolerance profile is favorable with lower percentages of patients with neutropenia (34.5%),&#xD;
      febrile neutropenia (3.5%), and neurotoxicity (5.2%).&#xD;
&#xD;
      The role of chemo-radiotherapy for LAPC remains controversial. Many old studies showed the&#xD;
      interest of this technique for the local and global control in patients with pancreatic&#xD;
      cancer.&#xD;
&#xD;
      However, a phase 3 study compared the efficacy of chemo-radiotherapy versus chemotherapy&#xD;
      alone in patients without disease progression after chemotherapy with a regimen that is&#xD;
      currently considered not optimal (i.e. gemcitabine with/without erlotinib). Although OS (the&#xD;
      main endpoint) did not improve in the chemo-radiotherapy arm compared with the chemotherapy&#xD;
      arm, PFS was significantly increased in the chemo-radiotherapy arm with a longer period&#xD;
      without treatment (6.1 vs 3.7 months, P = 0.02) and a lower percentage of patients with&#xD;
      locoregional progression (32% vs 46%, P =0.03). This confirms that radiotherapy is an&#xD;
      effective treatment in pancreatic adenocarcinoma, but that the current delivery modalities do&#xD;
      not allow significantly improving the patient prognosis. Indeed, the study used 3D conformal&#xD;
      radiotherapy with conventional doses and classical fractioning. Retrospective and phase 1 and&#xD;
      2 studies that used more optimized techniques and higher doses reported better local disease&#xD;
      control, but without an important impact on survival. Moreover, some studies suggest&#xD;
      significant toxicity, particularly in gastrointestinal organs. Intensity-modulated&#xD;
      radiotherapy and integrated boost radiotherapy showed promising local control and survival&#xD;
      results. This suggests an avenue for technological improvement and dose augmentation to&#xD;
      improve patient prognosis.&#xD;
&#xD;
      Stereotactic magnetic resonance-guided adaptive radiotherapy is a new modality for dose&#xD;
      delivery that exploits Magnetic Resonance Imaging (MRI)-guided linear accelerators to better&#xD;
      target the treatment volume, while optimizing the protection of organs at risk. The tumour&#xD;
      localization in the pancreas seems to be particularly suitable for the utilization of&#xD;
      MRI-guided linear accelerators because the radiotherapy doses are limited in function of the&#xD;
      gastrointestinal organ tolerance: duodenum, stomach, small intestine, colon. Recently, the&#xD;
      results of a retrospective, multicentre study on irradiation of patients with LAPC using&#xD;
      Magnetic Resonance Imaging (MRIdian® Linac™; Viewray. The study shows that survival was&#xD;
      improved in patients who received an augmented irradiation dose. Specifically, the 2-year OS&#xD;
      rate was 49% for patients who received a dose higher than 70 Gy and 30% for patients who&#xD;
      received a lower equivalent dose. The study did not report significant toxicity in patients&#xD;
      who received high-dose radiotherapy according to the optimized modalities with daily&#xD;
      dosimetric adjustment and target monitoring at each radiotherapy session. These data suggest&#xD;
      that dose intensification and the stereotactic magnetic resonance-guided adaptive&#xD;
      radiotherapy technique improve radiotherapy results; however, prospective studies are needed&#xD;
      to confirm these data.&#xD;
&#xD;
      Therefore, the phase 2 study GABRINOX-ART in which an intensified chemotherapy regimen&#xD;
      (GABRINOX i.e GA followed by FFX) is followed by optimized adjusted radiotherapy&#xD;
      (stereotactic magnetic resonance-guided adaptive radiotherapy) seems to be an interesting&#xD;
      strategy to evaluate in locally advanced pancreatic cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of non-progression at 4 months</measure>
    <time_frame>4 months</time_frame>
    <description>(Sequence 1 success = chemotherapy) according to the RECIST v1.1 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute gastrointestinal non-toxicity rate</measure>
    <time_frame>90 days</time_frame>
    <description>Absence of toxicity of grade ≥3 within 90 days, evaluated using the NCI-CTCAE v5.0 classification (sequence 2 success = radiotherapy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events due to chemotherapy by using the NCI-CTCAE version 5.0 scale</measure>
    <time_frame>36 months</time_frame>
    <description>Adverse events of chemotherapy evaluated using the NCI-CTCAE v5.0 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events due to radiotherapy by using the NCI-CTCAE version 5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Adverse events of radiotherapy evaluated using the NCI-CTCAE v5.0 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Through study completion, an average of 72 months</time_frame>
    <description>Between the date of inclusion and the date of the first documented progression or the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion, an average of 72 months</time_frame>
    <description>Interval between the date of inclusion and the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate</measure>
    <time_frame>From the end of radiotherapy (3 months) through 6 months post-radiotherapy</time_frame>
    <description>Percentage of patients who undergo tumour surgery up to 6 months post-radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthy margin resection rate (R0)</measure>
    <time_frame>From the end of radiotherapy (3 months) through 6 months post-radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic impact of CA 19-9 changes on survival</measure>
    <time_frame>Through study completion, an average of 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by using the quality of life questionnaire score (QLQ-C30)</measure>
    <time_frame>Through study completion, an average of 60 months</time_frame>
    <description>The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 (&quot;Not at all&quot;), 2 (&quot;A little&quot;), 3 (&quot;Quite a bit&quot;) and 4 (&quot;Very much&quot;). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.&#xD;
The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 (&quot;very poor&quot;) to 7 (&quot;excellent&quot;). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by using the quality of life questionnaire score (QLQ-PAN26)</measure>
    <time_frame>Through study completion, an average of 60 months</time_frame>
    <description>The QLQ-PAN26 uses for the question 31 to 56 a 4-point scale. The scale scores from 1 to 4: 1 (&quot;Not at all&quot;), 2 (&quot;A little&quot;), 3 (&quot;Quite a bit&quot;) and 4 (&quot;Very much&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events by using the NCI-CTCAE version 5.0 scale</measure>
    <time_frame>Through study completion, an average of 36 months</time_frame>
    <description>From inclusion of first patient until the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of planning target volume (PTV) coverage and dose received by the gross tumor volume (GTV) with progression free survival</measure>
    <time_frame>An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)</time_frame>
    <description>End of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of planning target volume (PTV) coverage and dose received by the gross tumor volume (GTV) with overall survival</measure>
    <time_frame>An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)</time_frame>
    <description>End of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the dose received by organs at risk (duodenum, small intestine, stomach, colon) with the appearance of gastrointestinal toxicities</measure>
    <time_frame>An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)</time_frame>
    <description>End of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summation of the dosimetric results in terms of dose/volume for the adaptive radiotherapy sessions and comparison with the predicted dosimetry</measure>
    <time_frame>An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)</time_frame>
    <description>End of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coverage of the planning targeted volume (PTV) by the prescription dose</measure>
    <time_frame>An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)</time_frame>
    <description>End of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose received by the gross total volume</measure>
    <time_frame>An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)</time_frame>
    <description>End of radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">103</enrollment>
  <condition>Locally Advanced Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gabrinox followed by stereotactic radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gembrax:&#xD;
Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest&#xD;
Folfirinox:&#xD;
Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Gabrinox</intervention_name>
    <description>Regimen: GEMBRAX&#xD;
Other Names:&#xD;
Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²&#xD;
Regimen: FOLFIRINOX&#xD;
Other Names:&#xD;
Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²&#xD;
Gembrax + Folfirinox = GABRINOX</description>
    <arm_group_label>Gabrinox followed by stereotactic radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI-GUIDED STEREOTACTIC RADIOTHERAPY</intervention_name>
    <description>Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.&#xD;
Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended.</description>
    <arm_group_label>Gabrinox followed by stereotactic radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient aged from 18 to 75 years at the date of signature of the consent form&#xD;
&#xD;
          2. Histologically or cytologically proven pancreatic adenocarcinoma&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          4. Non-resectable tumour according to the National Comprehensive Cancer Network (NCCN)&#xD;
             1.2015 recommendations after external review of imaging data by multidisciplinary&#xD;
             experts.&#xD;
&#xD;
          5. Non-metastatic cancer confirmed by thorax-abdomen-pelvis computerized tomography (CT)&#xD;
             scan and liver MRI&#xD;
&#xD;
          6. SMART feasibility confirmed by centralized review&#xD;
&#xD;
          7. Uracilemia &lt; 16 ng/ml&#xD;
&#xD;
          8. Hematological assessment within 14 days before inclusion, defined by:&#xD;
&#xD;
               -  Neutrophils ≥ 2 000/mm3 (2 × 109/L);&#xD;
&#xD;
               -  Platelets ≥ 100 000/mm3 (100 × 109/L);&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dl&#xD;
&#xD;
          9. Liver function (within 14 days before inclusion) defined by:&#xD;
&#xD;
               -  ASpartate Transaminase (AST) and ALanine Transaminase (ALT) ≤ 2.5 x Upper Limit&#xD;
                  of Normal (ULN);&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN. Patients with a metallic biliary prosthesis due to&#xD;
                  biliary obstruction caused by the cancer may be included, if: a CT scan with&#xD;
                  injection of contrast medium and thin pancreas sections was performed before&#xD;
                  placing the biliary prosthesis, the bilirubin level after prosthesis fitting&#xD;
                  decreased to ≤20 m /L (≤34 μmol/l), and in the absence of cholangitis.&#xD;
&#xD;
         10. Creatininaemia within the reference limits, or calculated clearance ≥50 ml/min for&#xD;
             patients with a serum creatinine value above or below the reference values (clearance&#xD;
             calculated using the Chronic Kidney Disease EPIdemiology collaboration (CKDEPI&#xD;
             formula).&#xD;
&#xD;
         11. Serum calcium AND magnesium AND potassium ≥ Lower Limit Normal (LLN and ≤ 1.2 x Upper&#xD;
             Limit Normal (ULN)&#xD;
&#xD;
         12. Cancer Antigen (CA 19.9) &lt;190 IU/mL (without cholestasis). Patients with CA 19.9&#xD;
             between 190 IU/mL and 500 IU/mL can be included if the Positron Emission Tomography&#xD;
             (PET) scan and peritoneal MRI do not detect any distant fixation, indicative of&#xD;
             metastasis. Patients with CA 19.9 ≥ 500 IU/mL cannot be included.&#xD;
&#xD;
         13. Sexually active patients must use a contraceptive method considered adequate and&#xD;
             suitable by the investigator during the entire period of administration of the study&#xD;
             treatment and up to 3 months after the treatment end. Moreover, female and male&#xD;
             patients must use a contraception method after the treatment end, as recommended by&#xD;
             the Summary of the product characteristics (SmPC) or prescription information included&#xD;
             in the study manual.&#xD;
&#xD;
         14. Signature of the consent form before any study-specific procedure.&#xD;
&#xD;
         15. Covered by the French health insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy,&#xD;
             surgery, targeted therapy, experimental therapy)&#xD;
&#xD;
          2. Gilbert's syndrome or homozygous Uridine DiPhosphate Glucuronosyl Transferase 1 A1&#xD;
             (UGT1A1 * 28)&#xD;
&#xD;
          3. Other concomitant cancer or history of cancer, except for treated in situ cancer of&#xD;
             the cervix , basal cell or squamous cell carcinoma, superficial bladder tumour (Ta,&#xD;
             Tis, and T1), or good-prognosis tumour cured without chemotherapy and without signs of&#xD;
             disease in the 3 years before inclusion&#xD;
&#xD;
          4. History of radiotherapy that causes a foreseeable overlap with the radiotherapy&#xD;
             treatment under study (history of abdominal irradiation)&#xD;
&#xD;
          5. Patients with high cardiovascular risk, including, but not limited to, coronary stent&#xD;
             or myocardial infarction in the past 6 months.&#xD;
&#xD;
          6. Peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          7. ECG with QTcorrected (QTc) interval longer than 450 ms for men and longer than 470 ms&#xD;
             for women&#xD;
&#xD;
          8. Contraindication to MRI and MRI-guided radiotherapy&#xD;
&#xD;
          9. History of chronic inflammatory disease of the colon or rectum&#xD;
&#xD;
         10. Any other concomitant and not controlled serious illness or disturbance that may&#xD;
             interfere with the patient's participation in the study and safety during the study&#xD;
             (e.g. severe liver, kidney, lung, metabolic, or psychiatric disorder)&#xD;
&#xD;
         11. Intolerance or allergy to one of the study drugs (gemcitabine, paclitaxel,&#xD;
             oxaliplatin, irinotecan, 5-FU) or to one of their excipients (e.g. fructose) listed in&#xD;
             the Contraindications or Warnings sections and Special precautions of the Summary of&#xD;
             Product Characteristics (SmPC) or prescription information&#xD;
&#xD;
         12. Legal incapacity (patient under guardianship or wardship)&#xD;
&#xD;
         13. Pregnant or breastfeeding woman. Fertile women must have a negative pregnancy test&#xD;
             (serum β-hCG) performed 72 hours before inclusion&#xD;
&#xD;
         14. Patient using vitamin K antagonists (Coumadin…) (possible modification of the&#xD;
             treatment before inclusion)&#xD;
&#xD;
         15. Active and uncontrolled bacterial or fungal infection that requires systemic&#xD;
             treatment.&#xD;
&#xD;
         16. History or known HIV infection&#xD;
&#xD;
         17. History of peripheral arterial disease (e.g. lameness, Buerger's disease).&#xD;
&#xD;
         18. Patient who received a attenuated live vaccine in the 10 days before inclusion&#xD;
&#xD;
         19. Patient with history of pulmonary fibrosis or interstitial pneumonia.&#xD;
&#xD;
         20. Inability to attend the follow-up visits due to geographic, social or mental reasons.&#xD;
&#xD;
         21. Participation in another clinical study with a research product during the last 30&#xD;
             days before inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne Portalès, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Cancérologie de Montpellier (ICM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Bleuse, MD</last_name>
    <phone>0467613102</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <state>Côte d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Ghiringhelli, MD</last_name>
      <email>FGhiringhelli@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Obled, MD</last_name>
      <email>stephane.OBLED@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Assénat, MD</last_name>
      <phone>04 67 33 67 33</phone>
      <phone_ext>+33</phone_ext>
      <email>e-assenat@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne Portalès, MD</last_name>
      <phone>0467612353</phone>
      <phone_ext>+33</phone_ext>
      <email>fabienne.portales@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétriêre</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Bachet, MD</last_name>
      <email>jean-baptiste.bachet@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.</citation>
    <PMID>28055103</PMID>
  </reference>
  <reference>
    <citation>Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016 Sep - Oct;55(9-10):1158-1160. doi: 10.1080/0284186X.2016.1197419. Epub 2016 Aug 23.</citation>
    <PMID>27551890</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.</citation>
    <PMID>30575490</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.</citation>
    <PMID>21561347</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.</citation>
    <PMID>24131140</PMID>
  </reference>
  <reference>
    <citation>Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.</citation>
    <PMID>27160474</PMID>
  </reference>
  <reference>
    <citation>Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, López-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294. doi: 10.1016/S2468-1253(19)30327-9. Epub 2020 Jan 14.</citation>
    <PMID>31953079</PMID>
  </reference>
  <reference>
    <citation>Kim YJ, Lee WJ, Woo SM, Kim TH, Han SS, Kim BH, Moon SH, Kim SS, Koh YH, Park SJ, Kim JY, Kim DY, Park JW. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2013 Jul 3;8:160. doi: 10.1186/1748-717X-8-160.</citation>
    <PMID>23822606</PMID>
  </reference>
  <reference>
    <citation>Huang J, Robertson JM, Margolis J, Balaraman S, Gustafson G, Khilanani P, Nadeau L, Jury R, McIntosh B. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol. 2011 May;99(2):114-9. doi: 10.1016/j.radonc.2011.05.038. Epub 2011 May 27.</citation>
    <PMID>21621866</PMID>
  </reference>
  <reference>
    <citation>Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.</citation>
    <PMID>23474363</PMID>
  </reference>
  <reference>
    <citation>Yang YF, Cao XH, Bao CE, Wan X. Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015 Nov 9;8:3315-22. doi: 10.2147/OTT.S91292. eCollection 2015.</citation>
    <PMID>26635481</PMID>
  </reference>
  <reference>
    <citation>Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324.</citation>
    <PMID>27139057</PMID>
  </reference>
  <reference>
    <citation>Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):313-322. doi: 10.1016/j.ijrobp.2016.10.030. Epub 2016 Oct 24. Review.</citation>
    <PMID>28068239</PMID>
  </reference>
  <reference>
    <citation>Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiat Oncol. 2019 Jun 6;14(1):95. doi: 10.1186/s13014-019-1309-x. Review.</citation>
    <PMID>31171025</PMID>
  </reference>
  <reference>
    <citation>Crane CH, O'Reilly EM. Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC). Cancer J. 2017 Nov/Dec;23(6):350-354. doi: 10.1097/PPO.0000000000000292. Review.</citation>
    <PMID>29189331</PMID>
  </reference>
  <reference>
    <citation>Acharya S, Fischer-Valuck BW, Kashani R, Parikh P, Yang D, Zhao T, Green O, Wooten O, Li HH, Hu Y, Rodriguez V, Olsen L, Robinson C, Michalski J, Mutic S, Olsen J. Online Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):394-403. doi: 10.1016/j.ijrobp.2015.10.015. Epub 2015 Oct 17. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):243.</citation>
    <PMID>26678659</PMID>
  </reference>
  <reference>
    <citation>Fischer-Valuck BW, Henke L, Green O, Kashani R, Acharya S, Bradley JD, Robinson CG, Thomas M, Zoberi I, Thorstad W, Gay H, Huang J, Roach M, Rodriguez V, Santanam L, Li H, Li H, Contreras J, Mazur T, Hallahan D, Olsen JR, Parikh P, Mutic S, Michalski J. Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system. Adv Radiat Oncol. 2017 Jun 1;2(3):485-493. doi: 10.1016/j.adro.2017.05.006. eCollection 2017 Jul-Sep.</citation>
    <PMID>29114617</PMID>
  </reference>
  <reference>
    <citation>Henke LE, Contreras JA, Green OL, Cai B, Kim H, Roach MC, Olsen JR, Fischer-Valuck B, Mullen DF, Kashani R, Thomas MA, Huang J, Zoberi I, Yang D, Rodriguez V, Bradley JD, Robinson CG, Parikh P, Mutic S, Michalski J. Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience. Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727. doi: 10.1016/j.clon.2018.08.010. Epub 2018 Sep 7.</citation>
    <PMID>30197095</PMID>
  </reference>
  <reference>
    <citation>Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, Green O, Michalski J, Mutic S, Parikh P, Olsen J. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018 Mar;126(3):519-526. doi: 10.1016/j.radonc.2017.11.032. Epub 2017 Dec 23.</citation>
    <PMID>29277446</PMID>
  </reference>
  <reference>
    <citation>Boldrini L, Cusumano D, Cellini F, Azario L, Mattiucci GC, Valentini V. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. Radiat Oncol. 2019 Apr 29;14(1):71. doi: 10.1186/s13014-019-1275-3. Review.</citation>
    <PMID>31036034</PMID>
  </reference>
  <reference>
    <citation>Bohoudi O, Bruynzeel AME, Meijerink MR, Senan S, Slotman BJ, Palacios MA, Lagerwaard FJ. Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. Radiother Oncol. 2019 Mar;132:16-22. doi: 10.1016/j.radonc.2018.11.019. Epub 2018 Dec 20.</citation>
    <PMID>30825964</PMID>
  </reference>
  <reference>
    <citation>El-Bared N, Portelance L, Spieler BO, Kwon D, Padgett KR, Brown KM, Mellon EA. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. Pract Radiat Oncol. 2019 Jan;9(1):e46-e54. doi: 10.1016/j.prro.2018.08.010. Epub 2018 Aug 25.</citation>
    <PMID>30149192</PMID>
  </reference>
  <reference>
    <citation>Luterstein E, Cao M, Lamb J, Raldow AC, Low DA, Steinberg ML, Lee P. Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. Cureus. 2018 Mar 14;10(3):e2324. doi: 10.7759/cureus.2324.</citation>
    <PMID>29765792</PMID>
  </reference>
  <reference>
    <citation>Olberg S, Green O, Cai B, Yang D, Rodriguez V, Zhang H, Kim JS, Parikh PJ, Mutic S, Park JC. Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer. Radiat Oncol. 2018 Mar 24;13(1):51. doi: 10.1186/s13014-018-1000-7.</citation>
    <PMID>29573744</PMID>
  </reference>
  <reference>
    <citation>Tyran M, Jiang N, Cao M, Raldow A, Lamb JM, Low D, Luterstein E, Steinberg ML, Lee P. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. Radiother Oncol. 2018 Nov;129(2):319-325. doi: 10.1016/j.radonc.2018.08.009. Epub 2018 Aug 30.</citation>
    <PMID>30174107</PMID>
  </reference>
  <reference>
    <citation>Rudra S, Jiang N, Rosenberg SA, Olsen JR, Roach MC, Wan L, Portelance L, Mellon EA, Bruynzeel A, Lagerwaard F, Bassetti MF, Parikh PJ, Lee PP. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019 May;8(5):2123-2132. doi: 10.1002/cam4.2100. Epub 2019 Apr 1.</citation>
    <PMID>30932367</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <keyword>cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

